Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing

    NEXT STORY
    Capital Senior Living Corporation Reports 2019 Second Quarter Results
    PREV STORY
    Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer

    Basel, 17 January 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...

    author_avatar
    NASDAQ Market News

    Innate Pharma First Quarter 2020 Report

    author_avatar
    NASDAQ Market News

    Steadman Philippon Research Institute Awarded First NIH Award

    author_avatar
    NASDAQ Market News